promisneurosciences.com - PMN Net Assets per Single Share

ProMIS Neurosciences (PMN) has no current sales, meaning its development relies entirely on attracting investment capital. The business prospects depend on the precision of its therapy for neurodegenerative pathologies. The book value per share in the daily price action on the GURU.Markets chart shows that the 5.47 level is recording fresh values. The clinic's success will provide the company with absolute pricing power due to the unique selectivity of its antibodies.

Accounting Value of a Share: ProMIS (PMN) for 06/27/2023 - 10/26/2026

ProMIS Neurosciences Inc. - analytical breakdowns and key metrics (PMN)

- price and consensus price forecast:

Price Chart ProMIS|PMN - Broker Consensus Forecast

- market capitalization data:

Market Value ProMIS Neurosciences, Inc.|PMN - Full Business Value

- book capitalization data:

Book Value per Share ProMIS Neurosciences|PMN - Accounting Value of Company|Market Capitalization to Book Value Ratio promisneurosciences.com|PMN - Company Total Assets

- debt and liquidity data:

Debt to Equity ProMIS Neurosciences|PMN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ProMIS|PMN - Company Total Debt|Debts to Book Capitalization ProMIS Neurosciences, Inc.

Analysis of all company metrics:promisneurosciences.com (PMN)

ProMIS Neurosciences (PMN) maintains a unique advantage in Alzheimer's therapy through its selective targeting technology for pathogenic proteins. An analysis of the book value per share, which has reached 5.47, reflects the dynamics of net assets, allowing for an assessment of the real capital cushion and resource management efficiency, which determines the biotech company's fundamental stability in the market over the long term.

Competitor analysis